Quick answer
How does melanotan II act at the molecular level, and how is that measured? It is a cyclic melanocortin agonist that engages G protein-coupled melanocortin receptors. Published work establishes its action through binding studies in cells expressing cloned receptors (MC1, MC3, MC5 and others), adenylate cyclase activation as a functional readout, and receptor-attribution experiments in which a selective antagonist reverses the effect (Chhajlani et al., 1993; Schiöth et al., 1995; Fan et al., 1997). This guide explains the assay chain: radioligand saturation and competition binding, cAMP accumulation, antagonist controls and the data analysis each requires, with formula-only arithmetic. For laboratory research use only; see the MT-2 product page and melanotan II research overview.
Mechanism of action for a receptor ligand is not a single fact but a set of measurements: does it bind, with what affinity, to which subtypes, what second messenger does it trigger, and can a selective blocker reverse the effect? This article follows that chain for melanotan II (MT-2) using the primary papers and the standard pharmacology formulas. It is written for a researcher setting up the assays, not for a general reader, and it avoids claims about physiology beyond what the cited abstracts report. The compound is supplied for laboratory research use only; not for human consumption.
The receptor family
The melanocortin system consists of five G protein-coupled melanocortin receptors, peptide agonists derived from the proopiomelanocortin precursor, and endogenous antagonists, the agouti proteins, which act at three of the five receptors (Cone, 2006). The first cloning of MSH and ACTH receptors defined the subfamily as G-protein-coupled (Mountjoy et al., 1992), and later cloning added further subtypes, including a receptor expressed in brain tissue but not in melanoma cells (Chhajlani et al., 1993). The numbering in older papers can differ from current MC1R to MC5R nomenclature, so a reader should match receptors by tissue and ligand profile, not by label alone.
Ligand specificity differs by subtype. In COS cells expressing MC1, MC3 and MC5 receptors, the MC1 and MC5 receptors showed a similar potency order to melanocortic peptides, with relatively higher affinity for alpha-MSH than for gamma-MSH or beta-MSH, while the MC3 receptor had higher affinity for desacetyl-alpha-MSH, gamma-MSH and beta-MSH than for alpha-MSH (Schiöth et al., 1995). A cyclic analog like MT-2 is therefore studied as a probe across subtypes, and its subtype profile must be established in each assay system. The structure that makes this possible is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, described on the MT-2 product page.
Binding assays: affinity and subtype comparison
The earliest receptor-level data used a radiolabeled relative of the compound family. In the cloning papers, the radioligand was [125I][Nle4, D-Phe7]-alpha-MSH, which bound a single saturable site with Kd values of 85.1 pM (MC1), 396 pM (MC3) and 5.05 nM (MC5) in COS cells (Schiöth et al., 1995), and bound the 1993 receptor with an affinity of 5.18 nM (Chhajlani et al., 1993). To characterize an unlabeled ligand such as MT-2, the standard approach is a competition assay in which increasing concentrations of the unlabeled compound displace a fixed amount of radioligand.
The key relationships are formulas, not product-specific numbers. The competition curve gives an IC50, which depends on the radioligand concentration used. The inhibition constant is calculated with the Cheng-Prusoff relation: Ki = IC50 / (1 + [L]/Kd), where [L] is the free radioligand concentration and Kd its dissociation constant measured by saturation binding. For saturation binding, the bound amount follows B = Bmax × [L] / (Kd + [L]). Both assume one site, equilibrium and negligible ligand depletion; an assay that breaks those assumptions needs a different analysis.
| Assay | What varies | What is fitted | Main assumption to check |
|---|---|---|---|
| Saturation binding | Radioligand concentration | Kd and Bmax | Equilibrium; low ligand depletion; specific binding defined by excess unlabeled ligand |
| Competition binding | Unlabeled compound concentration | IC50, converted to Ki | One site; equilibrium; radioligand below Kd |
| Kinetic binding | Time | kon and koff | Pseudo-first-order conditions |
| Subtype panel | Receptor subtype expressed | Rank order of affinity | Comparable expression levels across cell lines |
Functional readout: adenylate cyclase and cAMP
Binding alone does not say whether a ligand activates a receptor. The 1980 analog work measured activation of mouse melanoma adenylate cyclase and stimulation of tyrosinase in melanoma cells, alongside frog-skin darkening (Sawyer et al., 1980), establishing cyclic-AMP production as the functional readout for this peptide family. Modern assays measure intracellular cAMP accumulation in cells expressing a single receptor subtype, using a reporter or immunoassay, in the presence of a phosphodiesterase inhibitor so the signal accumulates.
A dose-response series is fitted with a four-parameter logistic model: E = E0 + (Emax − E0) / (1 + (EC50/[A])^n). EC50 is the concentration giving half-maximal response and Emax the plateau. Agonists should be compared as intrinsic activity relative to a reference agonist run on the same plate, since partial agonism cannot be seen in a single-ligand experiment. Controls to include are untransfected or parental cells (to rule out endogenous receptors), a reference agonist, forskolin for maximal adenylyl cyclase stimulation, and vehicle.
A practical note on concentration: the numbers in a dose-response are only as good as the stock. Dilutions should be prepared from a stock whose concentration is calculated with the calculator or the formula in peptide reconstitution volume calculations, using low-binding tubes for the dilute points because peptides adsorb to surfaces (Goebel-Stengel et al., 2011).
Receptor attribution with antagonists
To show that an effect is mediated by a specific receptor, a selective antagonist should shift or abolish it. Fan and colleagues provide the template. Using cyclic analogs identified as potent agonists or antagonists at neural MC3 and MC4 receptors, they found that intracerebroventricular administration of the agonist MTII inhibited feeding in four mouse models of hyperphagia (fasted C57BL/6J, ob/ob, A(Y) mice, and mice given neuropeptide Y), and that co-administration of the antagonist SHU9119 completely blocked the inhibition (Fan et al., 1997). They also reported that agouti peptide is a high-affinity antagonist of MC1-R and an antagonist of the hypothalamic MC4-R, which links the endogenous antagonist biology to the pharmacology of the analogs.
In cell systems the equivalent is a Schild analysis: dose-response curves for the agonist are measured at several fixed antagonist concentrations, and the rightward shift gives the dose ratio DR, from which log(DR − 1) = log[B] − log KB is plotted. A slope of one with parallel curves supports competitive antagonism and yields the antagonist's affinity constant KB. Slopes different from one suggest non-equilibrium conditions or more than one site.
The table gives a decision aid for interpreting results.
| Observation | Likely interpretation | Next experiment |
|---|---|---|
| Binding in a receptor-expressing line, none in parental line | Receptor-dependent binding | Subtype panel |
| cAMP rise blocked by antagonist | Receptor-mediated functional response | Schild analysis |
| cAMP rise not blocked by antagonist | Another receptor or non-receptor effect | Parental-cell and knockdown controls |
| High affinity but low Emax | Partial agonism | Compare to reference agonist, same plate |
| Different rank order of affinity across subtypes | Subtype-selective pharmacology | Check expression level equivalence |
Common pitfalls in melanocortin assays
- Endogenous receptor background. Many cell lines express some melanocortin receptor; parental controls are essential.
- Ligand depletion. High receptor density with low ligand volume can deplete the free ligand and distort Kd and Ki.
- Radioligand degradation. The 1995 paper reported that adding the endopeptidase inhibitor phosphoramidon to prevent breakdown of ACTH-(1-39) to alpha-MSH decreased its apparent binding affinity, showing that ACTH had a much lower affinity for MC1 than reported earlier (Schiöth et al., 1995). Ligand integrity during the assay can change the answer.
- Peptide adsorption. Dilute peptide solutions lose material to plastics and glass (Goebel-Stengel et al., 2011); work from freshly prepared dilutions.
- Species differences. Mouse and human receptors can differ in pharmacology, so state which was used.
- Over-reading central results. A feeding effect after intracerebroventricular delivery in mice shows a central receptor-dependent action in that model, nothing more.
Material integrity is the other half. Oxidation of the tryptophan residue is a recognized instability route for peptides (Li et al., 1995), and the lot documentation for the vial is part of the record: see how to read a COA and understanding HPLC purity.
Putting an assay panel together
A minimal, defensible panel for characterizing MT-2 in a new laboratory has four layers. First, binding in cells expressing each subtype of interest, with a reference radioligand and a competition series. Second, cAMP accumulation in the same cells with a reference agonist and forskolin. Third, an antagonist arm (a Schild-type experiment) on at least the subtype of primary interest. Fourth, a parental-cell and vehicle control on every plate. Replicates should be independent experiments, not wells from one experiment, and the dose-response should span at least four log units so plateaus are defined.
Document each step so results can be compared across batches: lot number, reconstitution date and solvent, storage history, passage number of cells, and the assay buffer. The MT-2 product page lists a 10 mg lyophilized powder of at least 98% purity by HPLC, stored at 2–8 °C or −20 °C long term and protected from heat, moisture and light; a COA is marked as coming soon there. Related reading: the purity testing article and the comparison with PT-141. Browse the shop for other research materials.
Frequently asked questions
What type of receptor does melanotan II act on?
The cited literature places it in the melanocortin family of G protein-coupled receptors (Mountjoy et al., 1992; Cone, 2006).
How is binding affinity measured?
With radioligand saturation and competition binding in cells expressing a cloned receptor, giving Kd and Ki.
What is the Cheng-Prusoff relation?
Ki = IC50 / (1 + [L]/Kd), converting a competition IC50 to an inhibition constant given the radioligand concentration and its Kd.
What functional readout is used?
Adenylate cyclase activation or cAMP accumulation, the readout used since the 1980 analog work (Sawyer et al., 1980).
How is a receptor-mediated effect proven?
By reversal with a selective antagonist, as with SHU9119 blocking MTII in the 1997 mouse feeding study (Fan et al., 1997), and by Schild analysis in cells.
Does the analog act on one receptor only?
The cited abstracts do not establish that. Subtype panels are needed because affinity differs between MC1, MC3 and MC5 (Schiöth et al., 1995).
Why include a parental cell control?
Cells may express endogenous melanocortin receptors that confound the signal.
What is a partial agonist?
A ligand whose maximal response is below that of a reference full agonist; it can only be seen by running both on the same plate.
Why does peptide adsorption matter?
Dilute solutions lose peptide to surfaces, so the concentration in the well can be lower than calculated (Goebel-Stengel et al., 2011).
What does agouti do?
In the 1997 abstract, agouti peptide is described as a high-affinity MC1-R antagonist and an antagonist of the hypothalamic MC4-R.
What are the product specifications?
10 mg lyophilized powder, at least 98% HPLC purity, formula C50H69N15O9, stored at 2–8 °C or −20 °C long term.
Responsible research use
Everything on this page is offered for laboratory research use only; it is background reading for qualified researchers, not guidance for any use outside a research setting, and nothing here is a claim about benefit in people or animals. Products from V8 Peptides are sold strictly as research materials: not a drug, food or cosmetic, and not for human or animal consumption. Published studies described here were run by their authors under their own approvals and protocols, and this page does not recommend repeating them.
Related reading: Reconstituted Melanotan II Stability: Study Design, Melanotan II Reconstitution Math and Study Reporting, Melanotan II Research Models: Cell Lines and Bioassays.
References
- Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, Hadley ME. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A. 1980;77(10):5754-5758. doi:10.1073/pnas.77.10.5754
- Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The cloning of a family of genes that encode the melanocortin receptors. Science. 1992;257(5074):1248-1251. doi:10.1126/science.1325670
- Chhajlani V, Muceniece R, Wikberg JES. Molecular cloning of a novel human melanocortin receptor. Biochem Biophys Res Commun. 1993;195(2):866-873. doi:10.1006/bbrc.1993.2125
- Schiöth HB, Muceniece R, Wikberg JES, Chhajlani V. Characterisation of melanocortin receptor subtypes by radioligand binding analysis. Eur J Pharmacol. 1995;288(3):311-317. doi:10.1016/0922-4106(95)90043-8
- Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 1997;385(6612):165-168. doi:10.1038/385165a0
- Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev. 2006;27(7):736-749. doi:10.1210/er.2006-0034
- Li S, Schöneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng. 1995;48(5):490-500. doi:10.1002/bit.260480511
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
